A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory Study of DSP-6952 in Patients with Irritable Bowel Syndrome with Constipatio
Phase 2
Completed
- Conditions
- Irritable bowel syndrome with constipation
- Registration Number
- JPRN-jRCT2080221995
- Lead Sponsor
- Sumitomo Dainippon Pharma Co.,Ltd.
- Brief Summary
DSP-6952 improved stool frequency as measured by CSBMs, abdominal symptoms, and overall IBS-C symptoms, and was well tolerated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 175
Inclusion Criteria
-Patients who meet the RomeIII criteria for irritable bowel syndrome with constipation
-Outpatients
etc.
Exclusion Criteria
- Patients who have history or complication of malignancy
- Patients who have history of medication allergy
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method